Why the FDA didn’t grant an approval to Lilly’s Alzheimer’s drug
January 20, 2023 at 09:23 AM EST
The regulator wants to see clinical data from at least 100 patients who have taken donanemab for a year
|
||||||||||||
![]() |
||||||||||||
|
||||||||||||
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Home | News | Travel | Restaurants | Nightlife | Things To Do | Shopping | Events | Directory | Real Estate | Blog | More
|